Dr. Carolyn Myers on FendX Technologies’ Breakthrough Film Formulation that Kills and Repels Bacteria

In an insightful interview with Tracy Weslosky from Investor.Coffee, Dr. Carolyn Myers, President, CEO, and Director of FendX Technologies Inc. (CSE: FNDX | OTCQB: FDXTF), shared significant advancements in nanotechnology relating to antimicrobial films. FendX, having licensed original technology from McMaster University in 2021, has developed a unique film formulation that both repels and kills bacteria. This breakthrough, achieved through collaboration with McMaster, involves using photoactive nanoparticles, titanium dioxide (TiO₂), which not only serves as a linker in the chemical composition of the film surface but also exhibits killing properties when exposed to light.

Dr. Myers highlighted the exceptional efficiency of this formulation, with the film showing nearly 100% repelling properties (99.8% precisely) and a 99.6% effectiveness in killing residual bacteria. This dual-action capability sets this formulation apart in the market, offering a potentially future superior alternative to existing films that either repel or kill pathogens. FendX’s current focus is on producing REPELWRAP™ film, which specializes in repelling bacteria and viruses.

The film formulation referenced in the November 29, 2023, news release, is created by activating the substrate (i.e., plastic like Saran wrap), then coating it with TiO₂ and fluorosilane followed by thermal shrinking creating a surface that significantly prevents bacterial adhesion. Dr. Myers contrasted FendX’s technology with other existing surface protection films that effectively kill microbes when they come in contact with the film surface, but this takes time leaving a potential window of opportunity for transmission before the bacteria are killed.

In terms of applications, Dr. Myers emphasized the potential versatility of FendX’s technology, with the company developing both film and spray products. The primary application areas include healthcare and other high-traffic environments. The spray technology, still in early development, promises even broader applications due to its ease of application.

To access the complete interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here

About FendX Technologies Inc.

FendX is a Canada-based nanotechnology company focused on developing products to make people’s lives safer by reducing the spread of pathogens. The Company is developing both film and spray products to protect surfaces from contamination. The lead product under development, REPELWRAP™ film, is a protective surface coating film that, due to its repelling properties, prevents the adhesion of pathogens and reduces their transmission on surfaces prone to contamination. The spray nanotechnology is a bifunctional spray coating being developed to reduce contamination on surfaces by repelling and killing pathogens. The Company is conducting research and development activities using its nanotechnology in collaboration with industry-leading partners, including McMaster University. The Company has an exclusive worldwide license to its technology and IP portfolio from McMaster, which encompass both film and spray coating nanotechnology formulations.

To learn more about FendX Technologies Inc., click here

Disclaimer: FendX Technologies Inc. is an advertorial member of InvestorNews Inc.

This interview, which was produced by InvestorNews Inc., does not contain, nor does it purport to contain, a summary of all material information concerning FendX Technologies Inc. (the “Company”), including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This interview and any transcriptions or reproductions thereof (collectively, this “presentation”) does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company’s profile on www.sedarplus.ca and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].